NCT07613216Not yet recruiting

A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension

Source: ClinicalTrials.gov · Last updated 29 May 2026

Brief summary (registry, in English)

This study will evaluate whether participants with serious lung diseases such as idiopathic pulmonary fibrosis, sarcoidosis, and pulmonary hypertension who use the FORTISKAP™ smart medication cap - a bottle-top device that tracks prescription bottle openings and sends dose reminders to participants and their care team - take their medications more consistently and experience better health outcomes compared to similar participants receiving standard care without the device. Participation requires no changes to prescribed medications, testing or clinical visits beyond what is already part of routine care; participants use a modified medication bottle equipped with the FORTISKAP™ cap for nine months.

Status (registry): Not yet recruiting
Study type: Observational
Enrollment: 100 (estimated)
First submitted: 9 May 2026
Start date: Jul 2026
Primary completion date: Jul 2027
Lead sponsor: Cosmos Rx, Inc
Diseases: Idiopathic pulmonary fibrosis, Pulmonary arterial hypertension, High blood pressure
NCT number: NCT07613216

What you commit to

Study type: Observational
Planned participants: 100
From Jul 2026 to the primary completion date, Jul 2027
1 site in 1 country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

Failure to meet any one of the above inclusion criteria

Who the study is looking for

21 years of age or older at time of enrollment
Primary diagnosis of interstitial lung disease (including sarcoidosis) AND/OR pulmonary hypertension
Currently managing their oral medications independently (i.e., without requiring caregiver administration)
At least one oral medication with a primary indication for treatment of ILD or PH already in use, or planned for initiation with insurance approval secured, at the time of enrollment
6-Minute Walk Test (6MWT) scheduled within the next 30 days or performed within the past 30 days
For ILD subjects: FVC and/or DLCO scheduled within the next 30 days or performed within the past 90 days
For PH subjects: Cardiac echocardiography scheduled within the next 30 days or performed within the past 90 days
Daily access to a smartphone compatible with the FORTISKAP™ companion application
Proficient in English

Age in the registry: 21 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

Site	City	Country	Site status
Pulmonary Disease Clinic, Sentara Norfolk Hospital Coordinator of this site? Confirm its status	Norfolk	United States	Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.